← Browse by Condition
Medical Condition

metastatic endocrine refractory

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07229417 Phase 2
Recruiting

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Enrollment
29 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →